More Than 11,000 Children Can Receive Free Dental Screenings

Posted on June 3, 2015

More Than 11,000 Children Can Receive Free Dental Screenings During Colgate’s Annual Oral Health Month Campaign Featuring TV Personality Karla Martinez

The Hispanic Dental Association Joins Colgate to Help Educate Hispanic Families About the Importance of Healthy Habits

PR Newswire – NEW YORK, NY (June 2, 2015) – Today, Colgate-Palmolive, in partnership with the Hispanic Dental Association (HDA), kicked off its annual Oral Health Month campaign with a special launch event at Los Angeles’s Plaza Mexico. To help raise awareness about the importance of a healthy smile, the Colgate Bright Smiles, Bright Futures® mobile dental van was on-site to provide bilingual learning materials and free dental screenings to children. Families in attendance also enjoyed a mariachi flash mob, live music and giveaways from local radio station, Univision 1020 AM.

“Our partnership with Colgate has given us the opportunity to address the various problems and adversities that contribute to poor oral health among the Latino population1,” said Vidal Balderas, President, Hispanic Dental Association. “Since the inception of Colgate’s Oral Health Month campaign, we have been able to screen more than thousands of children and inform parents of oral care best practices.”

Due to factors such as language barriers and lack of awareness about proper dental hygiene, a large percentage of U.S. Latinos tend to experience poor dental conditions and difficulty in accessing oral health education2. Colgate’s Oral Health Month aims to empower these consumers by providing the oral health tips and information they need.

“At Colgate, we are committed to our goal of making oral health a priority for families across the nation, and believe programs like our annual Oral Health Month campaign help equip families with the right information to implement healthy oral care habits that will last a lifetime,” said Carla Kelly, General Manager, U.S. Multicultural Marketing, Colgate-Palmolive.

Building off today’s event, Colgate will be engaging communities by distributing bilingual dental health information at major retailers and online. Additionally, more than 11,000 children can be reached with free dental screenings from Colgate Bright Smiles, Bright Futures®. Thanks to the dedicated dental professionals and HDA members, who volunteer aboard Colgate’s fleet of mobile dental vans, screenings have been scheduled in the Los Angeles, Houston, Miami and New York metro areas throughout the month of June.

To help encourage healthy brushing routines, Karla Martinez – Colgate spokesperson, TV personality and mother of two – will join families during the following Oral Health Month events in Houston, Texas:

  • Saturday, June 13, 12 p.m. – 2 p.m. 

    Fiesta Mart

    1603 Spencer Hwy

    Houston, TX 77587

  • Saturday, June 13, 4 p.m. – 6 p.m. 

    Fiesta Mart

    2323 Wirt Road

    Houston, TX 77055

For oral health tips in Spanish, follow and engage with Colgate on Twitter @SonrisaColgate.

To learn more about Colgate’s Oral Health Month, visit the campaign’s bilingual website at http://www.colgate.com/app/OralHealthMonth/US/ES/Home.cvsp or call 1-800-468-6502 to find out where free dental screenings will be available via Colgate’s Bright Smiles, Bright Futures van.

New Insight into Taste Bud Renewal Offers Hope for Cancer Patients with Taste Dysfunction

Posted on June 3, 2015

Cancer patients undergoing chemotherapy or radiotherapy often experience a reduction in their sense of taste. Now, researchers have uncovered a mechanism behind taste bud renewal, paving the way for new treatment strategies for patients with taste dysfunction.

Lead study author Dany Gaillard, of the Anschutz Medical Campus at the University of Colorado Denver, and colleagues publish their findings in the journal PLOS Genetics.

Taste buds are organs containing sensory cells that allow us to experience sweet, salty, sour, bitter and umami (savory) tastes. The majority of taste buds are on the surface of the tongue, though there are some in the cheek, epiglottis and the upper esophagus.

In total, adults have around 2,000-4,000 taste buds, which renew around once a week to maintain taste function. The exact process underlying taste bud renewal, however, has been unclear.

Many patients undergoing cancer treatment - particularly those who have head, neck or colon cancers - experience taste dysfunction. Some patients may be unable to taste at all, while others experience a metallic taste that can make it hard to swallow.

The cancer drugs used to kill cancer cells can damage healthy cells, including taste buds, impairing their ability to renew. "That in turn will alter a person's sense of taste [potentially] leading to malnutrition, weight loss and sometimes death," notes senior study author Linda Barlow, also of the Anschutz Medical Campus.

"Thus," the researchers add, "understanding how taste cells renew throughout adult life, i.e., how newly born cells replace old cells as they die, is essential to find potential therapeutic targets to improve taste sensitivity in patients suffering taste dysfunction."

Activating Wnt pathway could restore sense of taste for cancer patients

By analyzing the tongues of mouse models, the team found that the renewal of taste buds is controlled by a protein in the Wnt signaling pathway, called ß-catenin. This protein is key to producing taste buds in developing embryos, and it also regulates the renewal of epithelial tissue in adults, including that of the mouth, skin and hair follicles.

When it comes to taste bud renewal, the researchers found that ß-catenin regulates the individual stages of taste bud turnover to control their renewal.

"We show that activating this [Wnt] pathway directs the newly born cells to become primarily a specific taste cell type whose role is to support the other taste cells and help them work efficiently," explains Barlow.

As such, the researchers believe that one way to restore sense of taste in cancer patients undergoing treatment may be to activate the Wnt pathway, prompting taste bud renewal.

Based on their findings, the researchers hypothesize that small molecule cancer drugs that block the Wnt pathway may also cause taste dysfunction, meaning patients receiving such drugs would need complementary treatment to restore sense of taste.

While the team admits there is still much more to learn about the mechanisms underlying taste bud renewal, they believe their findings bring us a step closer to improving cancer patients' quality of life.

In June 2014, Medical News Today reported on a study that identified stress-activated hormones in the taste buds responsible for detecting sweet, umami and bitter tastes, which the researchers claim may explain emotional eating.

Source: Medical News Today

Acupuncture-like Electrical Nerve Stimulation May Help Dry Mouth

Posted on June 3, 2015

Phase III results of Radiation Therapy Oncology Group (RTOG) 0537 indicate that acupuncture-like, transcutaneous electrical nerve stimulation (ALTENS) may be equally effective as pilocarpine, the current prescription medication in a pill, to treat radiation-induced xerostomia (dry mouth), according to a study published in the June 1, 2015 issue of the International Journal of Radiation Oncology • Biology • Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO). RTOG 0537 is a phase II/III, multi-center, randomized trial comparing ALTENS with pilocarpine, which is the current standard of treatment for radiation-induced xerostomia.

RTOG 0537 was designed based on evidence published in 2003 (1) from a nonrandomized, phase II trial that ALTENS was a potential alternative treatment for radiation-induced xerostomia. ALTENS treats symptoms through electrodes placed on the skin at the locations of pre-selected acupuncture points. The electrodes deliver low-frequency, high-intensity pulses to stimulate acupuncture points in order to relieve the radiation-induced dry-mouth. Phase II results of RTOG 0537, published in 2012 (2), proved a positive response in patients who received ALTENS for radiation-induced xerostomia and demonstrated it was feasible to deliver ALTENS treatment in a multi-center trial.

The Phase III stage of the study accrued 148 patients from August 2010 to December 2011 at 13 cancer centers in the United States and Canada. Eligible patients had completed radiation therapy with or without chemotherapy three months to two years prior to enrolling in the study with no evidence of recurrence; reported grade 1 or higher xerostomia based on the Common Terminology Criteria for Adverse Events version 3.0; and had a Zubrod performance status of zero to two. (The Zubrod score indicates a patient's health status from zero to four, with zero indicating a patient is "fully active, able to carry on all pre-disease activities without restriction" and four indicating a patient is "completely disabled, cannot perform any self-care, and totally confined to bed or chair.") After enrollment, two patients were considered ineligible because their chemotherapy regiment or their physical examination and history were conducted outside of the maximum eight-week period before enrolling in the study.

Of the 146 patients included in the study, 73 patients were randomized to receive ALTENS, and 73 patients were randomized to receive pilocarpine. All patients began treatment within 14 days of enrolling. Patients in the ALTENS arm received two, 20-minute ALTENS sessions each week for 12 weeks (total of 24 ALTENS sessions). Patients were allowed two weeks of no treatment, and any missed sessions were rescheduled during the 12-week period; patients did not exceed three sessions per week. Patients in the pilocarpine arm received 5 mg of pilocarpine orally three times a day for 12 weeks; missed doses were not administered at a later time. Ninety-three percent (68) of patients in the ALTENS arm completed more than 85 percent of treatments, compared to 73 percent (53) of patients in the pilocarpine arm who completed more than 85 percent of the treatment.

Patients' xerostomia symptoms were assessed at baseline (before treatment) and at four, six, nine and 15 months after the patient's randomization date using the University of Michigan's Xerostomia-Related Quality of Life Scale (XeQOLS). XeQOLS is a patient-reported, 15-item scale that measures four domains: physical functioning, pain/discomfort, personal/psychologic functioning and social functioning. Patient responses to all four domains were averaged, and the total scores ranged from zero to four; an increased xerostomia burden is indicated by a higher score.

At nine months after randomization, 96 patients from both arms had completed all items to be included in the analysis. Four patients in the ALTENS arm and 11 patients in the pilocarpine arm had withdrawn from the trial. Five patients did not complete the baseline assessment prior to treatment, and 11 patients did not complete the XeQOLS prior to treatment. Six patients in the ALTENS arm and 13 in the pilocarpine arm either did not complete the XeQOLS or completed the XeQOLS outside of the designated time period.

In the 96 patients eligible for analysis, the mean baseline XeQOLS score of the ALTENS arm was slightly lower than the pilocarpine arm (1.5 compared to 1.7), which indicates a slightly higher quality of life for patients in the ALTENS arm. Baseline XeQOLS scores were subtracted from follow-up XeQOLS scores; a negative change would indicate improvement in xerostomia burden. At the nine-month follow-up (the study's primary endpoint), the median change in XeQOLS score was -0.53 for patients in the ALTENS arm and was -0.27 for patients in the pilocarpine arm. At follow-up 15 months from randomization, the median change in XeQOLS score was -0.60 for patients in the ALTENS arm and was -0.47 for patients in the pilocarpine arm. The median change in XeQOLS scores consistently improved for patients in the ALTENS arm, however, none of the differences were statistically significant. The proportions of patients who had 20 percent or more improvement from their baseline XeQOLS scores were consistently higher in the ALTENS arm and the difference was significant at 15 months from randomization.

Overall results yielded one grade three adverse event (headache) in the ALTENS arm, and two grade three adverse events (dry mouth and blurred vision) in the pilocarpine arm. In the ALTENS arm, 20.9 percent (15) of patients reported nonhematologic adverse events of grade three or less. In the pilocarpine arm, 61.6 percent (45) of patients reported nonhematologic adverse events of grade three or less. At follow-up nine months from randomization, there was no significant difference in the highest grade of adverse events related to treatment between the two arms of patients.

"Radiation-induced xerostomia is a challenging side-effect to treat because it makes it difficult and sometime painful for patients to swallow food, thereby affecting their nutrition and physical well-being. Oral pilocarpine and similar medications are not well tolerated by patients due to various side effects including sweating, diarrhea, frequent urination and dizziness. Multiple previous studies using needle acupuncture supported the potential for acupuncture approaches in treating xerostomia symptoms, so RTOG 0537 was developed to specifically explore those findings," said Raimond K.W. Wong, MBBS, the study's lead author, and a radiation oncologist and associate professor in the Department of Oncology at McMaster University in Hamilton, Ontario. "These phase III results of RTOG 0537 indicate that ALTENS, a needle-less acupuncture approach, could provide an alternative treatment option that has fewer side effects and, in turn, helps improve quality of life for patients with radiation-induced xerostomia. Some patients in the ALTENS group demonstrated lasting response and indicated the possibility to induce salivary gland tissue regeneration. Randomized, controlled, placebo trials are necessary to confirm ALTENS' treatment efficacy for painful, radiation-induced dry mouth, a debilitating condition for many patients."

Source: Science Daily

Academy of General Dentistry Mourns the Passing of Past President

Posted on June 2, 2015

CHICAGO (June 2, 2015)—The Academy of General Dentistry (AGD) mourns the unexpected passing of James “Jim” G. Richeson Jr., DDS, FAGD, of Chevy Chase, Md., past president of the AGD (2002 to 2003), who died on May 30, 2015, at the age of 61.

“Jim enriched the lives of everyone he knew,” says AGD President W. Carter Brown, DMD, FAGD. “He constantly put others before himself and cared deeply for his patients and family. His positive outlook on life was infectious. Jim’s life is one that should be admired and emulated.”

Dr. Richeson graduated from the former Georgetown University School of Dentistry in 1980 and opened his private practice the following year in Washington, D.C., following completion of a general practice residency at a Veterans Administration hospital in New Orleans. In addition to private practice, Dr. Richeson previously served as a clinical instructor and lecturer at his alma mater in the Department of Operative Dentistry.

Dr. Richeson was an active member of the AGD and received his Fellowship in 1986. He recently served as moderator for the AGD’s first Oral Health Symposium, which took place on April 24, 2015, at AGD Headquarters in Chicago. Previously, Dr. Richeson had served on the AGD’s first Oral Health Literacy Task Force. Dr. Richeson also served as AGD treasurer (1998 to 2000), as well as Region 5 trustee. Dr. Richeson held many other positions in the organization, including course chair for the AGD 1995 Annual Meeting & Exhibits, and member of the AGD Annual Meeting Council and AGD Awards Committee. He also served on the AGD Foundation Board of Directors. 

Dr. Richeson was active in other dental organizations as well, including the American Dental Association (ADA). He served as an ADA alternate delegate from 2001 to 2012. He also served as chair of the ADA Code Maintenance Committee in 2013 and took on the role of AGD representative to that committee in 2014. Dr. Richeson served as president for the District of Columbia AGD, the District of Columbia Dental Society, and the Georgetown University Alumni Club of Metropolitan Washington, D.C.

For his years of dedicated service to dentistry, Dr. Richeson received the District of Columbia Dental Society’s highest award for outstanding achievement in 2004. He also received a distinguished service award from the Georgetown Dental Alumni in 2003. He was a fellow of the American College of Dentists and the Pierre Fauchard Academy.

A devoted son of Mary Ann Neubeck Richeson and the late James G. Richeson, Dr. Richeson is survived by his wife, Anne “Nancy” C. Richeson, and daughter, Suzanne C. Richeson. Friends may visit the DeVol Funeral Home, 2222 Wisconsin Ave. N.W., Washington, D.C., on Thursday, June 4, from 6 to 8 p.m. A Mass of Christian burial will be offered at Holy Trinity Church, 3513 N St. N.W., Washington, D.C., on Friday, June 5, at 10 a.m. In lieu of flowers, contributions may be made to: Loyola Retreat House P.O. Box 9 Faulkner, MD 20632-009

AO Webinar: Creating a Team Approach for Best Implant Aesthetics

Posted on June 2, 2015

AskAO: How Do I Create a Team Approach for Best Implant Aesthetics?

Chicago, June 1, 2015 – Implant dentistry is an art as well as a science. As an implant specialist, you know your job is to provide an outcome superior in function, as well as form. To successfully do so requires a collaborative effort. Using a team approach to implant dentistry is essential to optimizing treatment outcomes for your patients.

But how do you employ a team approach and what are the best practices for creating this collaborative culture for the treatment?

As part of the new “You Ask! the Experts” webinar series for the Academy of Osseointegration (AO), implant experts Dr. Sonia Leziy and Dr. Brahm Miller shared three steps for creating this team approach:

1.    Include all involved parties in the treatment-planning phase. Be sure to include the patient, technician, and other specialists involved in the planning for procedures. Anticipating all the specifics from the start provides implant position accuracy and effective treatment with minimal hassles for the patient and the team.

2.    Communicate your needs to create the best outcome for the implant.Effective communication helps eliminate some of the problems with aesthetic outcomes.

·      Make clear what provides the best foundation for your treatment (i.e., soft tissue volume and restoration strategies).

·      Encourage the other specialists to provide the proper working base to create a better aesthetic outcome, a particularly important concern when you consider side-by-side implant cases with soft tissue challenges.

·      Include accurate impressions, which are facilitated best by a digital workflow.

3.    Keep a sense of urgency to the surgical strategy.Immediate implant placement is the best-case scenario for many cases. With the exception of cases where bone deficiency is too severe, most implants have the best outcome with an immediate placement protocol because this is when you have the most bone available.

Clinicians use experience and knowledge to create a successful outcome for patients. There are, however, many variables that create a successful outcome—and you don’t control all of them. By involving the other members of your team from the outset, communicating what you need to create the best implant treatment, and working for an immediate implant placement, you can use this team approach to create the best outcome for your patients for both form and function.

Members of the AO can download the webinar for free. Simply use your member login to the AO websiteand select the webinar to download to your device. Non-members may access itfor a $50 fee. AO is an ADA CERP Recognized Provider and designates the completion of this webinar activity for one-hour continuing education credit.

Register now for the next AO webinar titled “Guided Surgery: Heaven or Hell?” with Dr. Jaime Lozada, which will be presented on June24, 2015.  

 

About the Academy of Osseointegration

With 6,000 members in 70 countries around the world, the AO is recognized as the premier international association for professionals interested in implant dentistry. AO serves as a nexus where specialists and generalists can come together to evaluate emerging research, technology, and techniques,; share best information; and coordinate optimal patient care using timely, evidence-based science and methods. Follow AOon Facebookand Twitter.

Call for Abstracts: Academy of Osseointegration 2016 Annual Meeting

Posted on June 2, 2015

CHICAGO, June 2, 2015– Abstracts are now being accepted for the 2016 Annual Meeting of the Academy of Osseointegration (AO) occurring February 18-20 in San Diego. The theme of the meeting will be “Globalization of Implant Dentistry: A World of Collaboration.” Researchers who are interested in dental implants and tissue engineering are invited to submit an abstract online by 11:59 p.m. Central Time on Friday, August 28.

E-Posters were introduced at AO’s 2015 Annual Meeting for the first time. To digitally view some 300 E-Posters, visit www.osseo.org and click on the “View E-Posters” button.Search for each poster by its number, title, author or keyword. 

AO is currently accepting abstract submissions for E-Posters in the following categories:

·      Scientific research

·      Clinical research

·      Clinical innovations and case presentations

·      Systematic reviews including meta-analysis

·      Case studies

AO is also accepting submissions for oral presentations in the following categories:

·      Scientific research

·      Clinical research

·      Clinical innovations

To submit an abstract, visit www.osseo.org and click on the “2016 Annual Meeting Abstract Submission” button. Screen prompts will guide submitters through the process. There will be a $50 fee for all abstract submissions. Additional information regarding the E-Poster submission process will be sent in October once the presenter’s abstract has been accepted. 


AO’s Research Submissions Committee and the Clinical Innovations Committee will blindly review submitted abstracts for quality and appropriateness of content and presentation. Eight oral-clinical, eight oral-scientific and 20 clinical-innovation abstracts will be selected for presentation at the Annual Meeting.

During the event’s Annual Business Meeting on Saturday, February 20 awards and plaques will be presented for the best oral presentations and E-Posters. The best oral-scientific research and best oral-clinical research presentations will be awarded $1,000 and the best clinical-innovations presenter will receive $500. The first-place E-Poster will receive $500, second place $250, and the best case study will receive $500.

If members have questions about the oral presentations or E-Posters, they should contact Kim Scroggs, AO Manager of Education, at kimscroggs@osseo.org or at 847-439-1919.

Ruth Lipman, PhD, Becomes Director, Scientific Information at ADA

Posted on June 1, 2015

CHICAGO, May 26, 2015 — Dr. Ruth Lipman has accepted the role of Director, Scientific Information for The American Dental Association (ADA). In this role, Dr. Lipman will manage the development, review and publication of objective scientific information, providing the ADA membership with clinically relevant dental research and information.


"I’m thrilled to be part of the ADA," said Dr. Lipman. "I look forward to serving ADA members and leading the development of scientific information that will help promote better oral health."


Prior to joining the ADA, Dr. Lipman was the Chief Science and Practice Officer for the American Association of Diabetes Educators (AADE) where she oversaw research efforts, reviewed evidence for practice documents and worked to increase opportunities for diabetes educators. While at the AADE, Dr. Lipman was the Principal Investigator on projects that received awards from the Agency for Healthcare Research and Quality (AHRQ), Bristol-Meyers Squibb Foundation’s Together on Diabetes program and the Aetna Foundation. She was also the Principal Investigator on a cooperative agreement with the Centers for Disease Control that increased access to, participation in and sustainability of the National Diabetes Prevention Program.


Dr. Lipman has held various faculty appointments at Harvard University School of Medicine, Tufts University School of Nutrition and Worcester Polytechnic Institute. She received her Ph.D. in Biomedical Sciences and a Bachelor of Science in Life Sciences from Worcester Polytechnic Institute.

3M ESPE's Newest Curing Lights for Deep Curing and Polymerization

Posted on June 1, 2015

ST. PAUL, Minn. – June 1, 2015 – Dental professionals want predictability and confidence with their products and procedures, but sometimes the curing step can feel like a leap of faith. In fact, research shows that 69 percent of bulk fill users are not confident of polymerization deep in the cavity.1 If you can’t see under a restoration, how can you be sure it has cured properly and won’t break down prematurely? Now, with the new 3M™ ESPE™ Elipar™ DeepCure-S and Paradigm™ DeepCure LED Curing Lights, dental professionals can be more confident they have achieved a uniform and deep cure, even when they can’t get the light in a perfect position.

The new DeepCure LED Curing Lights have optimized optics, so they deliver a beam that is more uniform, with rays that stay more parallel and spread minimally as they travel away from the source. This creates a more even distribution of energy throughout the restoration, resulting in a complete and uniform cure from center to rim and from top to bottom—at clinically relevant distances. With the high-performing 1,470 mW/cm2 intensity, dental professionals can be sure of their cure.

“The well-balanced, ergonomic shape of the lights are comfortable for the operator, and performance is consistent regardless of the user,” said Nikki McKeon, U.S. marketer of direct restoratives for 3M ESPE Dental. “With improvements to the angle of the light guide, dentists now have easy access to all tooth surfaces, even hard to reach ones, which enhances overall patient comfort.”

The new lights are available in two models, both with identical technical performance. The Elipar DeepCure-S LED Curing Light is made with durable stainless steel, and has a charging base with built-in light meter indicating the operating status and light intensity. And the Paradigm DeepCure LED Curing Light gives dentists a lighter weight, economic model that is charged with a charging plug.

Both models provide intuitive two-button and single-mode operation, and no toggling between settings for optimal performance. The lights provide approximately 120 minutes of consecutive cordless curing time—that’s 720 10-second cures with constant light output, regardless of battery charge. The V-shaped handpiece and the 360° rotating light guide provide a comfortable grip, and the 10mm light guide provides a complete one-shot cure of MOD fillings.

With these new curing lights, dentists can be sure of their cure whether they use standard or bulk fill composites.

For more information, visit 3M.com/CuringLights.


About 3M ESPE Dental

3M ESPE is a dental product manufacturer that markets more than 2,000 dental products and services designed to help dental professionals improve their patients' oral health care. 3M ESPE is part of 3M Health Care, which provides world-class innovative products and services to help health care professionals improve the practice and delivery of patient care in medical, oral care, drug delivery and health information markets. For more information on the complete 3M ESPE line of dental products, visit the 3M ESPE website at http://www.3MESPE.com or call the 3M ESPE Technical Hotline at 1-800-634-2249. Products are available for purchase through authorized 3M ESPE distributors.

3M, ESPE, and Elipar are trademarks of 3M or 3M Deutschland GmbH. Used under license in Canada. © 3M 2015. All rights reserved.

About 3M

At 3M, we apply science in collaborative ways to improve lives daily. With $32 billion in sales, our 90,000 employees connect with customers all around the world. Learn more about 3M’s creative solutions to the world’s problems at www.3M.com or on Twitter @3M or @3MNewsroom.

 

Henry Schein's Disaster Relief Hotline Open to Customers Affected by South Central U.S. Storms

Posted on May 29, 2015

MELVILLE, NY, May 28, 2015 -- Henry Schein, Inc. (NASDAQ: HSIC), the world's largest provider of health care products and services to office-based dental, animal health and medical practitioners, today reminded its customers that the Henry Schein Disaster Relief Hotline is open for dentists, physicians and veterinarians who experience operational, logistical or financial issues as a result of the disastrous storms in the South Central region of the U.S. The toll-free number for all Henry Schein customers is 800-999-9729. The Hotline is operational from 7:00 a.m. to 7:00 p.m. ET.

"Our hearts and prayers are with the families of those who have lost their lives, or are still missing, as a result of the terrible storms and flooding that continue to ravage states in the South Central part of the U.S.," said Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein. "For our customers who have practices affected by the storms, we are here to help, and encourage practitioners to call our hotline for assistance."

In addition to opening its Disaster Relief Hotline, Henry Schein is offering support to its strategic non-governmental organization partners who are assessing the need for health care product donations to assist in relief efforts.

Because natural disasters, such as hurricanes, tornadoes and heavy storms typically strike many regions of the United States throughout the summer months, Henry Schein is reminding customers that its Disaster Relief Hotline will remain open to provide assistance to practitioners adversely affected by future disasters.

 

About Henry Schein, Inc.

Henry Schein, Inc. (NASDAQ: HSIC) is the world's largest provider of health care products and services to office-based dental, animal health and medical practitioners. The Company also serves dental laboratories, government and institutional health care clinics, and other alternate care sites. A Fortune 500® Company and a member of the S&P 500® and the NASDAQ 100® indexes, Henry Schein employs more than 18,000 Team Schein Members and serves more than one million customers.

The Company offers a comprehensive selection of products and services, including value-added solutions for operating efficient practices and delivering high-quality care. Henry Schein operates through a centralized and automated distribution network, with a selection of more than 100,000 branded products and Henry Schein private-brand products in stock, as well as more than 150,000 additional products available as special-order items. The Company also offers its customers exclusive, innovative technology solutions, including practice management software and e-commerce solutions, as well as a broad range of financial services.

Headquartered in Melville, NY, Henry Schein has operations or affiliates in 29 countries. The Company's sales reached a record $10.4 billion in 2014, and have grown at a compound annual rate of approximately 16 percent since Henry Schein became a public company in 1995. For more information, visit Henry Schein at www.henryschein.com, Facebook.com/HenrySchein and @HenrySchein on Twitter.

 

Keystone Holds Latin America Seminar

Posted on May 28, 2015

MIAMI, FL - Keystone Industries has been expanding its dental-industry boundaries wider than ever before over the past couple years and the impact was felt amongst members of the Latin America dental community this May.

The Sheraton Miami was home to Keystone Industries' first annual LATAM Dental Seminar, which was dedicated to customers from Central and South America. The seminar, which was held May 20-21, provided attendees all the necessary training and knowledge to take their dental businesses to the next innovative level by using the Keystone product lines. Guest speakers and presenters touched on all the big-sellers, as well as some lesser-known technologies looking to hit the ground running in the Latin American market.

Dennis Urban, CDT, a key opinion leader in the dental and denture field who has given lectures around the world, gave his presentation on removable technology followed by a live demonstration of denture processing with Diamond D acrylic and the Tecnoflask, Keystone's new microwavable denture flask.

Mike Prozzillo, VP of Sales, and Derek Keene, VP of Marketing, spoke to the attendees about mouthguards and thermoplastics Keystone offers, as well as how important Pro-Form mouthguard protection is to athletes in the United States.

“The movement for oral protection is spreading into Central and South America through sports like soccer, MMA fighting, and boxing. With our biggest and best customers from these countries south of the United States attending this seminar, it was very beneficial for their market,” Prozzillo said.  

Other speakers at the seminar included Sales Manager Wayne Allen, who shared knowledge and expertise of the acquired Bosworth product lines and the benefits it provides to dental practices, and Meg Shank of Apavia, a company that recently became an exclusive international partner with Keystone for water filtration technology, who spoke about the impact and importance of water filtration in dentist offices and how it will be growing over time.

Throughout the 2-day seminar, attendees were informed and trained on cutting-edge dental products and gave rave reviews of the overall event.

© 2015 AEGIS Communications | Privacy Policy